- Home
- NSPR vs HLVX Comparison
NSPR vs HLVX Comparison
Compare NSPR & HLVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NSPR
- HLVX
- Stock Information
- Founded
- NSPR 2005
- HLVX 2020
- Country
- NSPR Israel
- HLVX United States
- Employees
- NSPR N/A
- HLVX N/A
- Industry
- NSPR Medical/Dental Instruments
- HLVX Biotechnology: Pharmaceutical Preparations
- Sector
- NSPR Health Care
- HLVX Health Care
- Exchange
- NSPR Nasdaq
- HLVX Nasdaq
- Market Cap
- NSPR 75.6M
- HLVX 83.7M
- IPO Year
- NSPR N/A
- HLVX 2022
- Fundamental
- Price
- NSPR $2.58
- HLVX $1.39
- Analyst Decision
- NSPR Strong Buy
- HLVX Hold
- Analyst Count
- NSPR 2
- HLVX 5
- Target Price
- NSPR $4.75
- HLVX $2.33
- AVG Volume (30 Days)
- NSPR 67.4K
- HLVX 126.8K
- Earning Date
- NSPR 03-12-2025
- HLVX 03-28-2025
- Dividend Yield
- NSPR N/A
- HLVX N/A
- EPS Growth
- NSPR N/A
- HLVX N/A
- EPS
- NSPR N/A
- HLVX N/A
- Revenue
- NSPR $7,009,000.00
- HLVX N/A
- Revenue This Year
- NSPR $50.18
- HLVX N/A
- Revenue Next Year
- NSPR $159.56
- HLVX N/A
- P/E Ratio
- NSPR N/A
- HLVX N/A
- Revenue Growth
- NSPR 12.96
- HLVX N/A
- 52 Week Low
- NSPR $1.81
- HLVX $1.41
- 52 Week High
- NSPR $3.80
- HLVX $16.66
- Technical
- Relative Strength Index (RSI)
- NSPR 39.79
- HLVX 20.06
- Support Level
- NSPR $2.57
- HLVX $1.41
- Resistance Level
- NSPR $2.78
- HLVX $1.71
- Average True Range (ATR)
- NSPR 0.16
- HLVX 0.07
- MACD
- NSPR -0.01
- HLVX -0.03
- Stochastic Oscillator
- NSPR 31.82
- HLVX 7.50
About NSPR InspireMD Inc.
InspireMD Inc is a United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Italy, Germany, Russia and other countries.
About HLVX HilleVax Inc.
HilleVax Inc is a clinical-stage biopharmaceutical company. The company is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.